文献速递肝病消化道肿瘤与早癌

直接抗病毒药物治疗合并肝细胞癌的丙型肝炎患者疗效的系统综述与荟萃分析

Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma.
PubMed 文献 · Aliment Pharmacol Ther · 2019-12-06

BACKGROUND: Direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection is highly curative and tolerable. Among patients with hepatocellular carcinoma (HCC), optimal timing of DAA therapy remains unclear.…

要点

  • 合并HCC的HCV患者DAA治疗后总体SVR为88.3%。
  • 接受治愈性HCC管理或使用索非布韦+NS5A抑制剂方案者SVR更高。

核心结论

  • 合并HCC的HCV患者DAA治疗应答低于无HCC患者,且不受肝硬化状态影响。
  • 在HCC患者中,接受治愈性HCC管理的比例影响DAA治疗应答。

研究设计与样本

  • 系统综述与荟萃分析,检索文献数据库和会议摘要。

主要发现

  • 合并HCC患者总体SVR为88.3%(95%CI 86.1-90.4)。
  • 接受治愈性HCC管理的患者SVR为90.4%(95%CI 88.3-92.4)。
  • 使用索非布韦+NS5A抑制剂DAA的患者SVR为96.9%(95%CI 94.3-99.4)。
  • HCV基因1型感染患者SVR为92.0%(95%CI 88.1-95.6)。

临床怎么用

  • 对于合并HCC的HCV患者,DAA治疗前应综合考虑HCC管理状态以优化治疗时机。
  • 接受治愈性HCC管理后可考虑DAA治疗以提高SVR。
  • 索非布韦+NS5A抑制剂方案在HCC患者中显示较高SVR。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection is highly curative and tolerable. Among patients with hepatocellular carcinoma (HCC), optimal timing of DAA therapy remains unclear. Data on efficacy of DAA therapy in patients with HCC would inform this decision-making. AIM: To evaluate response to DAA therapy among patients diagnosed with HCV infection and HCC. METHODS: Bibliographic databases and conference abstracts were searched. Meta-analysis was conducted to pool sustained virologic response (SVR) estimates. RESULTS: Fifty-six studies with 5522 patients with HCV and HCC were included. Overall SVR was 88.3% (95% CI 86.1-90.4). Twenty-seven studies included patients with prior or present HCC (n = 3126) and patients without HCC (n = 49 138), in which SVR was 88.2% (95% CI 85.0-91.4) and 92.4% (95% CI 91.1-93.7) among patients with and without HCC, respectively (odds ratio: 0.54, 95% CI 0.43-0.68, P < .001). In the subgroup analyses, higher SVR was seen in patients who received curative HCC management (SVR 90.4%, 95% CI 88.3-92.4), or treated with sofosbuvir + NS5A inhibitor DAAs (SVR 96.9%, 95% CI 94.3-99.4), or in patients with HCV genotype 1 infection (SVR 92.0%, 95% CI 88.1-95.6). CONCLUSION: Response to DAA therapy was lower in patients with HCC compared to those without HCC, regardless of cirrhosis status. Among HCC patients, there was an impact of proportion with curative HCC management on DAA therapy response.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. He S, Lockart I, Alavi M, et al. Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma. Aliment Pharmacol Ther. 2019. PMID: 31808566. doi:10.1111/apt.15598

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。